USA - NASDAQ:KURA - US50127T1097 - Common Stock
KURA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While KURA seems to be doing ok healthwise, there are quite some concerns on its profitability. KURA does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -64.54% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Altman-Z | -0.72 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.16 | ||
| Quick Ratio | 6.16 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.39 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:KURA (10/27/2025, 2:12:05 PM)
10.465
+0.77 (+7.89%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.91 | ||
| P/FCF | 7.39 | ||
| P/OCF | 7.27 | ||
| P/B | 2.97 | ||
| P/tB | 2.97 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.89% | ||
| ROE | -64.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 147.53% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.08 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 241.96% | ||
| Cap/Sales | 2.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.16 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | -0.72 |
ChartMill assigns a fundamental rating of 3 / 10 to KURA.
ChartMill assigns a valuation rating of 2 / 10 to KURA ONCOLOGY INC (KURA). This can be considered as Overvalued.
KURA ONCOLOGY INC (KURA) has a profitability rating of 1 / 10.
The financial health rating of KURA ONCOLOGY INC (KURA) is 6 / 10.